SUPPLEMENTARY APPENDIX

IMPACT OF CONDITIONING INTENSITY AND GENOMICS ON RELAPSE AFTER ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME

Laura W. Dillon Ph.D., Gege Gui Sc.M., Brent R. Logan Ph.D., Mingwei Fei M.Sc., Jack Ghannam B.S., Yuesheng Li Ph.D., Abel Licon M.S., Edwin P. Alyea M.D., Asad Bashey M.D. Ph.D., Steven M. Devine M.D., Hugo F. Fernandez M.D., Sergio Giralt M.D., Mehdi Hamadani M.D., Alan Howard Ph.D., Richard T. Maziarz M.D., David L. Porter M.D., Erica D. Warlick M.D., Marcelo C. Pasquini M.D., Bart L. Scott M.D., Mitchell E. Horwitz M.D., H. Joachim Deeg M.D., Christopher S. Hourigan DM DPhil

Table of Contents

SUPPLEMENTARY METHODS

SAMPLES AND DNA ISOLATION

Pre-conditioning baseline whole blood samples were collected a median of 12 days (100% within 30 days) prior to the date of transplantation. High quality genomic DNA (gDNA) was extracted from all 48 available frozen 1mL aliquots using the SPRI-TE gDNA Extraction kit (cat# A50087, Beckman Coulter, Inc., Brea, CA) on the SPRI-TE nucleic acid extractor (Beckman Coulter, Inc., Brea, CA). DNA concentration was measured using the Quant-iT PicoGreen dsDNA Assay kit (cat# P11496, Thermo Fisher Scientific, Waltham, MA) on the Synergy LX microplate reader (BioTek Instruments, Inc., Winooski, VT).

TARGETED NEXT-GENERATION SEQUENCING (NGS)

A custom anchored multiplex PCR based targeted DNA sequencing panel (VariantPlex, ArcherDx, Boulder, CO) was designed with coverage of 29 commonly mutated genes in Myelodysplastic Syndrome (MDS) (**supplementary Table 1**).

Libraries were prepared according manufacturer's instructions, with modifications, utilizing pre- and post-PCR separation on liquid handling robots. 200-ng of gDNA isolated from whole blood was brought to 50-µL using 10mM Tris-HCl pH 8.0 and was subjected to DNA fragmentation, end repair, A-tailing, purification using SPRIselect reagent (cat# B23318, Beckman Coulter, Inc., Brea, CA), and ligation with a universal ArcherDx molecular barcode (MBC) adapter, which tags each DNA molecule with a unique molecular index (UMI) and allows for unidirectional amplification of the sample using gene-specific primers. Following molecular barcode ligation, the libraries were subjected to two rounds of nested PCR for target enrichment. DNA fragmentation, end repair, cleanup after end repair, ligation step 1, cleanup after ligation step 1, MBC adapter incorporation, ligation step 2, cleanup after ligation step 2, and setup of first PCR were all performed on a Sciclone G3 NGS Workstation (PerkinElmer Health Sciences, Inc., Shelton, CT). Cleanup after first PCR, second PCR, and cleanup after second PCR were all performed on an epMotion 5075 (Eppendorf AG, Hamburg, Germany). Incubations and PCR reactions were performed on a Mastercycler X50a (Eppendorf AG, Hamburg, Germany). For the first PCR, amplification was performed as follows: 95°C for 3 minutes; 16 cycles of 95°C for 30 seconds, 63°C for 5 minutes; 72°C for 3 minutes. For the second PCR, amplification was performed as follows: 95°C for 3 minutes; 22 cycles of 95°C for 30 seconds, 65°C for 5 minutes; 72°C for 3 minutes.

The resulting libraries were subjected to paired-end 150-bp sequencing on a HiSeq 2500 in Rapid Run mode (Illumina, San Diego, CA), according to manufacturer's instructions. Libraries were sequenced in batches of 8 per lane, each with a unique dual index. A total of 108 million paired-end reads were acquired across the 48 MDS patient samples, with an average of 43 million paired-end reads per sample (**supplementary Table 2**). FASTQ files are available in the NCBI Small Reads Archive (SRA) (Accession: PRJNA644802).

NEXT GENERATION SEQUENCING DATA ANALYSIS

Raw sequencing FASTQ files were analyzed using the Archer Analysis software version 6.0.2.3, using default settings. The only exception was that the deep shallow threshold

3

was set to 3 (defining a deep error-correctable bin as ≥ 3 reads per molecular barcode/UMI). DNA structural variation and SNP-InDel pipelines were utilized.

Preprocessing

Pre-processing steps include read cleaning, deduplication and error correction, read mapping, *de novo* and targeted variant calling, and variant annotation. During read cleaning, all reads were filtered based on Illumina's base quality calls and the presence of the appropriate Archer chemistry read signatures. Additionally, pairs of reads were aligned to determine overlap between R1 and R2. If overlap occurred, any discordant bases between R1 and R2 were converted to N's. Next, de-duplication and error correction of PCR duplicates was performed by extracting UMI read families and generating a single high-fidelity consensus read for use in downstream analysis. Any singleton reads were used as is, but not considered a deep bin $(\geq 3 \text{ reads per molecular})$ barcode). All reads (consensus and singleton) were then mapped to the human genome version hg19 (build GRCh37) using a combination of Bowtie2 and BWA-Mem. For the 48 MDS patient sample libraries, there was an average of 35 million mapped paired-end reads with an average on-target deduplication ratio of 6.9 (**supplementary Table 2**). Across all positions in the panel, there was a mean de-duplicated depth of 7,148 and a mean deep, error-correctable depth $(\geq 3$ reads per molecular barcode) of 3.429 (**supplementary Table 2**).

Variant calling was then performed on the aligned reads using *de novo* and targeted variant calling algorithms. *De novo* variant calling was performed using both Freebayes and LoFreq algorithms, with a minimum allele frequency for variant calling set to 0.001.

4

To improve coverage of well characterized insertion variants within the *NPM1* gene with established low background in our assay, targeted variant calling was performed by providing a VCF file with well-established *NPM1* variants to guarantee metrics were computed and supplied as an output in the bioinformatic pipeline. Annotation of variants was performed using the Variant Effect Predictor (VEP) algorithm.

FLT3-ITD mutations were detected using a structural variation algorithm. Beginning with deduplicated reads, clustering was performed for each gene specific primer, beginning with R2 reads and then assembled with their companion R1 reads using Velvet, creating a set of contigs for each R2/R1 cluster. Contigs were grouped together by target gene and merged based on pairwise local alignment, repeating until no further merges could take place. Contigs with low coverage, short length, or alignment to known transcripts or the reference genome were removed. The remaining sequences were annotated using NCBI blastn and those contigs sharing a breakpoint were merged. For each structural variant remaining, reads with coverage spanning the primary breakpoint by at least 20 bp were used to calculate the frequency of the mutation.

Error modeling

Following pre-processing, an outlier detection algorithm was performed to determine positions that have more alternate observations than would be expected due to error. In the outlier detection algorithm, two types of background error estimates are made. One based on all reads and another based only on consensus reads that originated from multiple PCR duplicates (i.e. deep bins with \geq 3 reads per molecular barcode/UMI). Using

5

the outlier detection algorithm, a position-specific background noise models based on a binomial distribution were generated for variants called in each sample compared to the Normal Data Set (ND). The ND background error model was generated using a set of 4 wild-type libraries made from gDNA isolated from the blood of de-identified normal donors, and corrected for the majority of errors introduced during library preparation, sequencing, and data analysis. For each variant called in a sample, a P value was calculated based on the ND background error models.

Variant filtering

De novo **variants**

Variants called by the *de novo* variant algorithms (LoFreq and Freebayes) underwent a first round of filtering in order to: 1) remove anomalies generated as the result of library preparation and sequencing; and 2) select for variants associated with leukemic progression. The following filter conditions were applied in step 1:

- 1. Deep Alternate Observations (DAO) \geq 5
	- a. The number of consensus reads that come from deep molecular families must be greater than or equal to 5. A molecular family is considered deep if there are greater than or equal to 3 reads per UMI.
- 2. Unique Start for Alternate Observation (UAO) \geq 5
	- a. The total number of unique starts across all reads that contained the alternate observations must be greater than or equal to 5.
- 3. gnomAD $AF \leq 0.005$
- a. The population frequency of the variant in gnomAD database must not exceed 0.005.
- 4. VEP Consequence = coding sequence variant, feature elongation, feature truncation, frameshift variant, incomplete terminal codon variant, inframe_deletion, inframe_insertion, missense_variant, protein_altering_variant, start lost, stop gained, stop lost, transcript ablation, transcript amplification, splice acceptor variant, or splice donor variant, splice region variant
	- a. The VEP consequence of any known isoform affected by the variant must include one of these consequences.
- 5. Has Sample Strand Bias = No
	- a. There must be no significant bias from primers that prime off of opposing strands.
- 6. Has Sequencing Direction Bias = No
	- a. There must be no significant bias from read pairs when using Illumina's paired-end chemistry
- 7. $AF \geq 0.001$, excluding AF between 0.48 and 0.52
	- a. The AF of the variant must be greater than 0.001, but not be between 0.48 and 0.52 for exclusion of probable germline variants
- 8. HRUN < 9
	- a. The variant must not be flanked by a homopolymer run of greater than 8 bases.
- 9. ND background noise $(BN) \leq 0.001$
- a. The ND error model position-specific background noise for all read families must be less than or equal to 0.001.
- 10. ND Deep Allele Frequency (DAF) outlier P value ≤ 0.0001
	- a. The ND background error model P value for deep consensus read families must be less than or equal to 0.0001.
- 11.Median distance from start site > 20
	- a. The median distance of the variant to the start site generated by random ligation of the molecular barcode adapter must be greater than 20.

All remaining *de novo* variants underwent manual curation to remove any remaining chemistry-related artifacts and to reannotate complex insertion-deletion variants present on the same allele.

Targeted variants

Targeted variants called within the *NPM1* gene had the following filters applied:

- 1. Alternate Observations $(AO) \geq 3$
- 2. VEP Consequence = frameshift_variant

STATISTICAL ANALYSIS

Clinical characteristics of the 48 patients were compared with those of the 54 MDS patients in the original clinical trial using student's t-test or Mann-Whitney U test for continuous variables, and chi-squared test or Fisher's exact test for categorical variables. The same methods were applied for the baseline characteristics comparison of reduced intensity conditioning (RIC) and myeloablative conditioning (MAC) patients, NGS positive and NGS negative patients.

The study of different clinical outcomes included the Kaplan-Meier estimation with logrank test for overall survival (OS) and relapse-free survival (RFS), the Gray's test for competing risks of treatment-related mortality (TRM) and relapse. The analysis was using the long-term Center for International Blood and Marrow Transplant Research (CIBMTR) data with P values reported, and the visualization was plotted at 3 years.

Two-sided P values <0.05 were considered significant. Statistical analysis and data visualization were performed with R software (version 3.6.0; R Foundation for Statistical Computing, Vienna, Austria) with its packages^{$1-8$}.

Supplementary Figure 1. Differences in overall survival, relapse, and transplant-related mortality between MAC and RIC censored at 18 months.

Rates of overall survival, relapse, and transplant related mortality for patients randomized to myeloablative conditioning (MAC; blue) and reduced intensity conditioning (RIC; yellow) are shown for the 54 myelodysplastic syndrome (MDS) patients in the original clinical trial (A) and the 48 MDS patients in the clinical cohort used in this study (B).

Supplementary Figure 2. Clinical outcomes by mutation type, frequency, and cooccurrence.

(A) The allele frequency of each mutation detected in each gene in the blood of myelodysplastic syndrome patients prior to transplantation is shown, with shapes indicating conditioning intensity and color indicating relapse outcome. (B) The percentage of patients with mutations in each gene is shown, separated by conditioning intensity. Red, relapse; Blue, no relapse; Grey, treatment related mortality (TRM).

Supplementary Figure 3. Clinical outcomes by disease classification, disease risk group, and cytogenetic risk group.

Models for overall survival (OS) and relapse were generating based on (A) disease classification (Group 1 [good risk] = Refractory Anemia with Ringed Sideroblasts and Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts; Group 2 [evolving] = Refractory Anemia with Excess Blasts - 1 (5-9% blasts) and Refractory Anemia with Excess Blasts - 2 (10-19% blasts); and Group 3 [other] = Refractory Anemia, Refractory Cytopenia with Multilineage Dysplasia, MDS Unclassified, and MDS Associated with Isolated Del(5q)), (B) disease risk group, and (C) cytogenetic risk group.

Supplementary Figure 4. Clinical outcomes by 10-gene mutational status and poor risk cytogenetics.

Patients were grouped into categories based on NGS mutational status and cytogenetic risk group. Patients were considered positive (Positive/Poor) if they had a mutation detectable in the blood by next-generation sequencing (NGS) within the 10-gene panel (*FLT3, IDH1, IDH2, JAK2, KIT, NPM1, NRAS, RUNX1, SF3B1,* and *TP53*) or had poor risk cytogenetics prior to conditioning and the remaining patients were considered negative. Models for rates of treatment related mortality (TRM), relapse, relapse-free survival (RFS), and overall survival (OS) were generated for (A) Positive/Poor versus negative status and (B) by conditioning intensity (reduced intensity conditioning [RIC] or myeloablative conditioning [MAC]).

Supplementary Figure 5. Clinical outcomes by mutational classifications.

Patients were grouped into different categories based on the presence of mutations in groups of genes. Patients without mutations in any groups of genes were categorized as next-generation sequencing (NGS) negative. Models for overall survival (OS) and relapse were generated based on NGS positivity and conditioning intensity (reduced intensity conditioning [RIC] or myeloablative conditioning [MAC]) for patients with mutations in (A) 10-gene panel (*FLT3, IDH1, IDH2, JAK2, KIT, NPM1, NRAS, RUNX1, SF3B1,* and *TP53*), (B) *DTA* (DNMT3A, TET2, and ASXL1) only, and (C) 16-gene panel only (*BCOR*, *CBL*, *CUX1*, *ETV6*, *EZH2*, *GATA2*, *KRAS*, *PHF6*, *PPM1D*, *PTPN11*, *SETBP1*, *SRSF2*, *STAG2*, *U2AF1*, *WT1*, *ZRSR2*).

Supplementary Figure 6. Clinical outcomes by variant allele frequency.

Patients were grouped into categories based on the highest variant allele frequency (VAF) of a mutation detected within any of the 29 gene regions sequenced in the blood prior to conditioning. Patients with at least one mutation with a VAF \geq 2.5% were classified as next-generation sequencing (NGS) positive and the remaining as NGS negative. Models for treatment related mortality (TRM), relapse, relapse-free survival (RFS), and overall survival (OS) were generated based on (A) NGS mutational status and (B) NGS mutational status and conditioning intensity (reduced intensity conditioning [RIC] or myeloablative conditioning [MAC]).

Supplementary Table 1. Regions of interest in 29-gene targeted DNA sequencing panel.

Supplementary Table 2: Sample sequencing summary (n = 48)

Unique molecular index, UMI

Supplementary Table 3 Variants detected by next-generation sequencing in the blood of EXABLE 3. Variants detected by next-generation sequencies of MDS patients prior to conditioning.

Supplementary Table 4. Sensitivity and specificity of NGS mutational status prior to conditioning for predicting MDS patient relapse at 24 months. 24 months.

10-gene panel: FLT3, IDH1, IDH2, JAK2, KIT, NPM1, NRAS, RUNX1, SF3B1, and TP53
13-gene panel: 10-gene panel plus DNMT3A, TET2, and ASXL1
26-gene panel: 10-gene panel plus BCOR, CBL, CUX1, ETV6, EZH2, GATA2, KRAS, PHF6, PPM

10-gene high VAF (variant allele frequency): at least one variant detectable at VAF ≥ 2.5% in the 10-gene panel
10-gene panel + poor cytogenetics: 10-gene panel plus patients with poor risk cytogenetics present prior to h

SUPPLEMENTARY REFERENCES

1. Alboukadel Kassambara MK: survminer: Drawing Survival Curves using 'ggplot2'. R package version 0.4.3., 2018

2. Gray B: cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-7, 2014

3. Kolde R: pheatmap: Pretty Heatmaps. R package version 1.0.10, 2018

4. Wickham H: Reshaping data with the reshape package. Journal of Statistical Software 21, 2007

5. Wickham H: Ggplot2 : elegant graphics for data analysis. New York, Springer, 2009

6. Wickham H: stringr: Simple, Consistent Wrappers for Common String Operations. R package version 1.4.0, 2019

7. Xie Y: Dynamic documents with R and Knitr (ed Second edition.). Boca Raton, CRC Press/Taylor & Francis, 2015

8. Zhang Z: Reshaping and aggregating data: an introduction to reshape package. Ann Transl Med 4:78, 2016